Immix Biopharma Inc (IMMX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immix Biopharma Inc (IMMX) has a cash flow conversion efficiency ratio of -0.051x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.74 Million) by net assets ($228.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IMMX market cap overview for the company's overall valuation and market capitalisation.
Immix Biopharma Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Immix Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Immix Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immix Biopharma Inc ranked by their cash flow conversion efficiency. See IMMX debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Luzerner Kantonalbank AG
LSE:0QNU
|
0.004x |
|
Hangzhou Weiguang Electronic Co Ltd
SHE:002801
|
0.045x |
|
Minerals 260 Ltd
AU:MI6
|
-0.038x |
|
Tian Jin Motor Dies Co Ltd
SHE:002510
|
0.053x |
|
Magazine Luiza S.A
SA:MGLU3
|
0.400x |
|
Zhejiang Oceanking Development Co Ltd
SHG:603213
|
0.065x |
|
IPERIONX LTD SP.ADR/10
F:30Z0
|
N/A |
|
Apotea
ST:APOTEA
|
0.080x |
Annual Cash Flow Conversion Efficiency for Immix Biopharma Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Immix Biopharma Inc from 2019 to 2025. View today's stock price for Immix Biopharma Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $93.80 Million | $-23.93 Million | -0.255x | +76.84% |
| 2024-12-31 | $13.25 Million | $-14.60 Million | -1.101x | -56.94% |
| 2023-12-31 | $16.20 Million | $-11.37 Million | -0.702x | -24.66% |
| 2022-12-31 | $13.16 Million | $-7.41 Million | -0.563x | -537.23% |
| 2021-12-31 | $17.99 Million | $-1.59 Million | -0.088x | -203.27% |
| 2020-12-31 | $-4.73 Million | $-404.69K | 0.086x | -60.52% |
| 2019-12-31 | $-3.65 Million | $-790.03K | 0.217x | -- |
About Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.